An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies
نویسندگان
چکیده
منابع مشابه
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Recombinant immunotoxins are fusion proteins that contain the cytotoxic portion of a protein toxin fused to the Fv portion of an antibody. The Fv binds to an antigen on a target cell and brings the toxin into the cell interior, where it arrests protein synthesis and initiates the apoptotic cascade. Moxetumomab pasudotox, previously called HA22 or CAT-8015, is a recombinant immunotoxin composed ...
متن کاملCAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.
PURPOSE To compare the in vitro and in vivo efficacy of CAT-8015, a second-generation recombinant immunotoxin composed of disulfide-linked affinity matured V(H) and V(L) chains of the mouse anti-CD22 monoclonal antibody RFB4 fused to PE38, to the parental compound CAT-3888. EXPERIMENTAL DESIGN The biological activity of CAT-8015 was examined in vitro using B-cell tumor lines and in vivo in a ...
متن کاملConstruction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM
Epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein overexpressed in human epithelioma but with relatively low expression in normal epithelial tissues. To exploit this differential expression pattern for targeted cancer therapy, an EpCAM-targeted immunotoxin was developed and its antitumor activity was investigated in vitro. An immunotoxin (scFv2A9-PE or APE) was co...
متن کاملImmunotoxin therapy of hematological malignancies.
everal years have passed since the potential for unconjugated monoclonal antibodies (mAbs) to selectively target malignant cells was first described. Although the concept behind serotherapy is theoretically simple, the overall clinical results in these studies have often been disappointing and numerous obstacles have emerged due to the difficulty in penetrating tumor masses, the limited inheren...
متن کاملAnti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
PURPOSE Although most children with B-lineage acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma are cured, new agents are needed to overcome drug resistance and reduce toxicities of chemotherapy. We hypothesized that the novel anti-CD22 immunotoxin, RFB4(dsFv)-PE38 (BL22, CAT-3888), would be active and have limited nonspecific side effects in children with CD22-expressing hematologic ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia Research
سال: 2014
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2014.06.014